SEC Form 4 · accession 0001178913-26-004299
MediWound Ltd. · MDWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shmuel Hess
Officer — COO & Chief Commercial Officer
Period of report
Aug 26, 2026
Accepted (ET)
Aug 28, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001593984
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF8 | Aug 26, 2026 | S | 1,865 | $13.00 | D | 0 | D | |
| Ordinary SharesF9 | Aug 27, 2026 | S | 1,979 | $12.72 | D | 0 | D | |
| Ordinary SharesF9 | Aug 27, 2026 | S | 1,979 | $13.126 | D | 0 | D | |
| Ordinary SharesF1,F10 | holding | — | — | — | 4,085 | D | ||
| Ordinary SharesF2,F10 | holding | — | — | — | 3,000 | D | ||
| Ordinary SharesF3,F10 | holding | — | — | — | 3,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy ordinary shares)F4,F8 | $8.1292 | Aug 26, 2026 | M | 5,000 | D | — | Dec 1, 2033 | Ordinary Shares | 5,000 | 27,000 | D |
| Stock Option (right to buy ordinary shares)F4,F9 | $8.1292 | Aug 27, 2026 | M | 11,000 | D | — | Dec 1, 2033 | Ordinary Shares | 11,000 | 16,000 | D |
| Stock Option (right to buy ordinary shares)F5,F10 | $12.729 | holding | — | — | — | — | Feb 26, 2034 | Ordinary Shares | 32,681 | 32,681 | D |
| Stock Option (right to buy ordinary shares)F6,F10 | $18.54 | holding | — | — | — | — | Feb 11, 2035 | Ordinary Shares | 24,000 | 24,000 | D |
| Stock Option (right to buy ordinary shares)F7,F10 | $17.60 | holding | — | — | — | — | Mar 4, 2036 | Ordinary Shares | 31,000 | 31,000 | D |
Explanation of responses
- F1The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F10There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only.
- F2The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F3The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F4The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F5The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F6The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F7The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F8The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
- F9The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.